diagnosis
Malignant glioma comprises glioblastoma [World Health Organization (WHO) grade IV], anaplastic astrocytoma (WHO grade III), mixed anaplastic oligoastrocytoma (WHO grade III) and anaplastic oligodendroglioma (WHO grade III). Diagnosis after biopsy or tumor resection is made according to the revised WHO classification. Prognosis depends on tumor grade and histology. Glioblastoma carries the worst prognosis, whereas pure oligodendroglioma tends to have a better outcome and improved response to therapy. Prognosis of mixed anaplastic oligoastrocytoma and anaplastic astrocytoma is intermediate between glioblastoma and pure anaplastic oligodendroglioma.
molecular markers
Genetic loss on chromosomes 1p/19q [loss of heterozygosity (LOH) 1p/19q], recently recognized as a chromosomal translocation has been suggested as a marker for responsiveness to chemotherapy. However, it describes a distinct tumor entity with a prolonged natural history irrespective of treatment, its chemo-responsiveness may be due to the high correlation with methyl-guanine methyl transferase (MGMT) promoter methylation. LOH 1p/19q should be performed to support a diagnosis of oligodendroglioma.
Epigenetic silencing of the MGMT gene promoter by methylation indicates a partial inability of the tumor to repair the chemotherapy-induced DNA damage. In retrospective analyses it has been strongly correlated with outcome to alklyating agent chemotherapy [ 
treatment plan
Patients should be evaluated by a specialized multidisciplinary team. Special consideration needs to be given to performance status and neurological function. High doses of corticosteroids (usually dexamethasone 8-16 mg/day) will allow the rapid reduction of tumor-associated edema and improve clinical symptoms. Patient glucose level needs to be monitored, there is no need for prolonged steroid therapy after tumor resection or prophylaxis during radiotherapy: Antiepileptic therapy is indicated in patients presenting with an initial seizure, however prophylactic antiepileptic therapy before or after surgery is not needed in asymptomatic patients [III, C]. After tumor resection, the indication for anti-seizure therapy should be revisited. First generation antiepileptic drugs (phenytoin, carbamazepin, phenobarbital and their derivates) are strong inducers of the hepatic metabolism and may interfere with many concomitant medications, including many commonly used chemotherapy agents (but not with temozolomide).
newly diagnosed patients
Surgery is commonly the initial therapeutic approach for tumor debulking and obtaining tissue for diagnosis. Tumor resection is of prognostic value; it may be beneficial to attempt maximal tumor resection provided that neurological function is not compromised by the extent of resection [II, C]. Implantation of chemotherapy-impregnated wafers (carmustine polymer) into the resection cavity before radiotherapy has shown to improve marginally the median survival compared with radiotherapy alone [ 
recurrent disease
Some benefit of chemotherapy has been shown for patients with an adequate performance status who have not received prior adjuvant cytotoxic therapy. Anaplastic astrocytomas are more likely than glioblastoma to respond to temozolomide chemotherapy [III, B] . For patients progressing after prior chemotherapy, there is no established chemotherapy regimen available and patients are best treated within investigational clinical protocols. Single-agent nitrosourea therapy may improve tumor control in some patients, while randomized trials have failed to demonstrate measurable anti-tumor efficacy of epidermal growth factor receptor (EGFR) inhibition by erlotinib or platelet-derived growth factor receptor (PDGFR) inhibition by imatinib in an unselected patient population [II, C]. High response rates and a steroid-sparing effect have been observed with the administration of bevacizumab (6 irinotecan), however, the effect is frequently short-lived and may be largely due to changes in vascular permeability without necessarily translating into a prolonged survival [III, C] .
Repeat surgery and implantation of chemotherapyimpregnated polymers may prolong survival in selected patients [II, B] .
response evaluation
If response is evaluated, it should be done with MRI. Contrast enhancement and presumed tumor progression on imaging 4-8 weeks after the end of radiotherapy may be an imaging artefact (pseudoprogression) and should be re-evaluated 4 weeks later with a second MRI. In case of doubt in patients with early progression after the end of radiotherapy, chemotherapy should be pursued as planned.
Response to chemotherapy is evaluated according to the WHO criteria, but should also include an assessment of neurological function and corticosteroid use (Macdonald criteria) . The rate of patients alive and progression free at 6 months (PFS6mo) has been recognized as a valid endpoint and also includes patients who benefit from therapy by disease stabilization. However, with the frequent use of anti-angiogenic and vasculature modifying agents this endpoint may need to be revisited.
follow-up
Follow-up consists of a clinical evaluation with particular attention to neurological function, seizures or seizure equivalents and corticosteroid use. Patients should be tapered off steroid use as early as possible. Venous thrombotic events occur frequently in patients with unresected or recurrent tumors.
Laboratory tests are not indicated unless the patient is receiving chemotherapy (blood counts), corticosteroids (glucose) or antiepileptic drugs (blood count, liver function tests).
For imaging, MRI is recommended. Repeat MRI every 3-4 months is standard practice outside clinical trials, unless more frequent monitoring is clinically indicated. 
